One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration
Author:
Funder
NIH
NEI
Research to Prevent Blindness
Regeneron Pharmaceuticals, Inc
Publisher
Elsevier BV
Subject
Ophthalmology
Reference18 articles.
1. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration;Heier;Ophthalmology,2012
2. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006
3. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006
4. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study;Schmidt-Erfurth;Ophthalmology,2011
5. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1;Regillo;Am J Ophthalmol,2008
Cited by 73 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Simultaneous Intravitreal Steroid and Anti-VEGF Therapy for Monotherapy-Resistant Chronic Wet Age-Related Macular Degeneration;Ophthalmic Surgery, Lasers and Imaging Retina;2024-08
2. Short-Term Real-World Outcomes of Intensive Aflibercept Injection for Refractory Neovascular Age-Related Macular Degeneration;Journal of Clinical Medicine;2024-06-15
3. Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes;Medicine;2024-04-19
4. Chrysin alleviates DNA damage to improve disturbed immune homeostasis and pro-angiogenic environment in laser-induced choroidal neovascularization;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-03
5. Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab;Journal of Clinical Investigation;2023-01-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3